Inhibitory effects of antithrombin on the expression of secretory group IIA phospholipase A(2) in endothelial cells

BMB Rep. 2010 Sep;43(9):604-8. doi: 10.5483/BMBRep.2010.43.9.604.

Abstract

Tumor necrosis factor-α (TNF-α) mediates proinflammatory responses in primary human umbilical vein endothelial cells (HUVECs), and it upregulates the expression of secretory group IIA phospholipase A(2) (sPLA(2)-IIA). sPLA(2)-IIA plays a pivotal role in inflammation, and antithrombin (AT) possesses properties that are beneficial to endothelial cells. Therefore, we investigated the effects of AT on the expression of sPLA(2)-IIA in TNF-α-stimulated HUVECs. TNF-α potently upregulated the expression of sPLA(2)-IIA, and prior treatment of cells with AT inhibited the expression of sPLA(2)-IIA in HUVECs. Also, antibodies or siRNA for syndecan-4 blocked the protective effect of AT. Furthermore, PI3-kinase and the AKT pathway are significantly involved in the AT-mediated inhibition of the expression of sPLA(2)-IIA. These results show that AT effectively suppresses the upregulated sPLA(2)-IIA expression, which might contribute to the cytoprotective effects of AT in the treatment of severe inflammatory diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antithrombins / pharmacology*
  • Blotting, Western
  • Cells, Cultured
  • Endothelial Cells / drug effects*
  • Endothelial Cells / enzymology*
  • Enzyme Activation / drug effects
  • Enzyme Activation / genetics
  • Enzyme-Linked Immunosorbent Assay
  • Group II Phospholipases A2 / metabolism*
  • Humans
  • Inhibitory Concentration 50
  • RNA, Small Interfering
  • Syndecan-4 / genetics
  • Syndecan-4 / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antithrombins
  • RNA, Small Interfering
  • SDC4 protein, human
  • Syndecan-4
  • Tumor Necrosis Factor-alpha
  • Group II Phospholipases A2